Crescent Biopharma (CBIO) Non Operating Income (2013 - 2026)
Crescent Biopharma (CBIO) reported Non Operating Income of $1.4 million for Q1 2026, up 256.49% year-over-year from $405617.5 in Q1 2025, and up 607.37% on a QoQ basis from -$285000.0 in Q4 2025.
Crescent Biopharma (CBIO) has 10 years of Non Operating Income data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Non Operating Income rose 256.49% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (up 535.52% YoY) and the FY2025 annual result came in at -$690000.0, down 131.94% from the prior year.
- Non Operating Income improved to $1.4 million in Q1 2026 per CBIO's latest filing, from -$285000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.4 million in Q1 2026 and bottomed at -$924000.0 in Q1 2025.
- The 4-year median for Non Operating Income is $561586.0 (2023), against an average of $319271.5.
- The widest annual swing landed in 2025, when Non Operating Income slumped 142.16%; it then soared 256.49% in 2026.
- Tracing CBIO's Non Operating Income over 4 years: stood at $512194.0 in 2023, then surged by 31.98% to $676000.0 in 2024, then tumbled by 142.16% to -$285000.0 in 2025, then soared by 607.37% to $1.4 million in 2026.
- Per Business Quant, the three latest CBIO Non Operating Income figures stand at $1.4 million (Q1 2026), -$285000.0 (Q4 2025), and $1.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 444,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 201.20 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | -46.98 Mn |
| 10 | Crescent Biopharma | 569.36 Mn | 380.20 Mn | - | 1.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.45 Mn |
| Dec 31, 2025 | -285,000.00 |
| Sep 30, 2025 | 1.28 Mn |
| Jun 30, 2025 | -760,000.00 |
| Mar 31, 2025 | -924,000.00 |
| Dec 31, 2024 | 676,000.00 |
| Dec 31, 2023 | 512,194.00 |
| Sep 30, 2023 | 610,978.00 |
| Sep 30, 2018 | 944,409.00 |
| Jun 30, 2018 | 870,139.00 |
| Mar 31, 2018 | 363,704.00 |
| Dec 31, 2017 | 278,004.00 |
| Sep 30, 2017 | 231,634.00 |
| Jun 30, 2017 | 102,079.00 |
| Mar 31, 2017 | 39,495.00 |
| Dec 31, 2016 | 29,673.00 |
| Sep 30, 2016 | 32,063.00 |
| Jun 30, 2016 | 21,813.00 |
| Mar 31, 2016 | 20,097.00 |
| Dec 31, 2015 | 5,823.00 |
| Sep 30, 2015 | 3,302.00 |
| Jun 30, 2015 | 2,638.00 |
| Mar 31, 2015 | 3,564.00 |
| Dec 31, 2014 | 4,378.00 |
| Sep 30, 2014 | 4,827.00 |
| Jun 30, 2014 | 4,263.00 |
| Mar 31, 2014 | 4,773.00 |
| Dec 31, 2013 | 14.00 |
| Sep 30, 2013 | 16.00 |
| Jun 30, 2013 | -104.00 |
| Mar 31, 2013 | 965.00 |